SCHEDULE: Aquilo Capital Divests Entire Stake in Precision Bio

Aquilo Capital and its affiliates have reported a complete divestment of their beneficial ownership in Precision Biosciences Inc., reducing their stake to 0.0%.

Summary

• Aquilo Capital, L.P., Aquilo Capital Management, LLC, and Marc Schneidman (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G.
• The filing indicates that the Reporting Persons no longer beneficially own any shares of Precision Biosciences Inc. Common Stock, with their aggregate ownership reduced to 0.0%.
• This amendment updates their previous beneficial ownership report for Precision Biosciences Inc. (CUSIP 74019P207).

Sentiment

Score: 3

Explanation: The sentiment is negative due to the complete divestment of shares by a reporting entity, which typically signals a lack of confidence or a strategic exit from the investment.

Negatives

• The complete divestment of beneficial ownership by Aquilo Capital and its affiliates, reducing their stake to 0.0%, can be perceived as a negative signal regarding their confidence in Precision Biosciences Inc.

Future Outlook

No forward-looking statements or guidance were provided in this beneficial ownership filing.

Industry Context

This filing reflects a change in institutional investor holdings, which is a common occurrence in the public markets and does not directly relate to broader industry trends or competitor performance, other than indicating a specific investor's decision regarding their portfolio allocation.

Stakeholder Impact

• Shareholders may interpret the complete divestment by Aquilo Capital as a negative signal, potentially impacting investor confidence and the company's stock price.

Key Dates

Recommendation

The complete divestment of shares by a previously significant beneficial owner, Aquilo Capital, indicates a strong negative signal from an institutional investor. This action suggests a lack of confidence in the company's future prospects or a strategic decision to exit the investment entirely. Such a move by a reporting entity can lead to decreased investor sentiment and potential downward pressure on the stock price, warranting a 'sell' recommendation for investors considering the implications of this divestment.

Keywords

Precision Biosciences, Aquilo Capital, Beneficial Ownership, SEC Filing, Schedule 13G, Divestment, Common Stock, Institutional Investor